CSPC Pharmaceutical Group Limited (CHJTF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CSPC Pharmaceutical Group Limited (CHJTF) with AI Score 50/100 (Hold). CSPC Pharmaceutical Group Limited is a leading Chinese pharmaceutical company focused on the research, development, and manufacturing of a diverse range of pharmaceutical products. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026CSPC Pharmaceutical Group Limited (CHJTF) Healthcare & Pipeline Overview
CSPC Pharmaceutical Group Limited stands out in the healthcare sector as a prominent pharmaceutical manufacturer, offering a broad portfolio of innovative products targeting critical health conditions, while maintaining a robust market presence in China and expanding internationally.
Investment Thesis
CSPC Pharmaceutical Group Limited demonstrates strong growth potential driven by its diverse product portfolio and expanding international presence. The company has a market capitalization of $11.65 billion and a P/E ratio of 22.48, indicating investor confidence in its future earnings growth. With a profit margin of 14.9% and a gross margin of 66.7%, CSPC showcases operational efficiency and profitability. Key growth catalysts include the increasing demand for innovative healthcare solutions in China and beyond, as well as potential expansions into new markets. Additionally, CSPC's focus on research and development positions it well to capitalize on emerging healthcare trends. However, the company must navigate regulatory challenges and competitive pressures within the pharmaceutical industry, which could impact its growth trajectory.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $11.65 billion reflects strong investor confidence.
- P/E ratio of 22.48 indicates favorable valuation compared to industry peers.
- Profit margin of 14.9% showcases effective cost management and operational efficiency.
- Gross margin of 66.7% exceeds industry averages, highlighting product profitability.
- Dividend yield of 2.63% provides a return to shareholders amid growth.
Competitors & Peers
Strengths
- Diverse product portfolio catering to various health conditions.
- Strong market presence in China and expanding internationally.
- High gross margin indicating effective cost management.
- Commitment to innovation through significant R&D investments.
Weaknesses
- Dependence on the Chinese market for a large portion of revenue.
- Potential regulatory challenges in international markets.
- Exposure to patent expiration risks affecting product sales.
- Limited brand recognition outside of Asia.
Catalysts
- Upcoming: Expansion into new international markets to drive revenue growth.
- Ongoing: Continuous investment in R&D to develop innovative therapies.
- Ongoing: Strengthening partnerships with healthcare providers for product distribution.
- Upcoming: Launch of new products targeting chronic disease management.
- Ongoing: Focus on enhancing operational efficiencies to improve profit margins.
Risks
- Potential: Regulatory challenges in international markets may hinder growth.
- Ongoing: Intense competition from established pharmaceutical companies.
- Potential: Patent expirations could impact revenue from key products.
- Ongoing: Economic fluctuations affecting healthcare spending and pricing.
Growth Opportunities
- Expansion into international markets: CSPC is poised to capitalize on its existing product portfolio by entering new international markets. The global pharmaceutical market is expected to grow at a CAGR of 6.3% from 2021 to 2028, presenting significant opportunities for CSPC to increase its market share and revenue streams.
- Investment in R&D for innovative therapies: CSPC's commitment to research and development is a key driver for future growth. By focusing on the development of novel therapeutics, particularly in oncology and neurology, the company aims to address unmet medical needs and enhance its competitive positioning in the market.
- Increasing demand for chronic disease management: With rising incidences of chronic diseases such as diabetes and hypertension, CSPC's product offerings in these therapeutic areas are well-positioned to meet growing healthcare demands. The global diabetes market alone is projected to reach $100 billion by 2025, providing CSPC with ample growth potential.
- Strategic partnerships and collaborations: CSPC can enhance its growth trajectory through strategic partnerships with other pharmaceutical companies and research institutions. Collaborations can facilitate access to new technologies, expand product offerings, and accelerate time-to-market for innovative therapies.
- Focus on functional foods and healthcare services: The growing trend towards preventive healthcare and wellness presents an opportunity for CSPC to expand its functional food and healthcare services segments. The global functional food market is expected to reach $275 billion by 2025, allowing CSPC to diversify its revenue streams.
Opportunities
- Expansion into emerging markets with growing healthcare needs.
- Development of innovative therapies in high-demand therapeutic areas.
- Increasing demand for functional foods and preventive healthcare solutions.
- Strategic partnerships to enhance product offerings and market reach.
Threats
- Intense competition from domestic and international pharmaceutical companies.
- Regulatory changes impacting drug approval processes.
- Market fluctuations affecting pricing and profitability.
- Risks associated with supply chain disruptions and sourcing materials.
Competitive Advantages
- Strong brand recognition within the Chinese pharmaceutical market.
- Extensive product portfolio addressing a wide range of health conditions.
- Established relationships with healthcare providers and distributors.
- Commitment to research and development fostering innovation.
- Operational efficiencies leading to favorable profit margins.
About CHJTF
CSPC Pharmaceutical Group Limited, founded in 1992 and headquartered in Shijiazhuang, China, is an investment holding company that specializes in the research, development, manufacture, and sale of pharmaceutical products. Originally known as China Pharmaceutical Group Limited, the company rebranded to its current name in March 2013 to reflect its growth and international ambitions. CSPC operates through three main segments: Finished Drugs, Bulk Products, and Functional Food and Others. Its extensive product portfolio includes treatments for acute ischemic stroke, mild to moderate memory impairment, Parkinson's disease, various cancers, and more. The company has developed notable products such as NBP soft capsules, Oulaining capsules, and Duomeisu, which address significant health challenges. CSPC's commitment to innovation and quality has positioned it as a key player in the pharmaceutical industry, not only in China but also across other Asian regions, the Americas, and Europe. With a workforce of approximately 21,400 employees, CSPC is dedicated to enhancing healthcare outcomes through its diverse range of pharmaceutical offerings and healthcare services.
What They Do
- Research and develop a wide range of pharmaceutical products.
- Manufacture finished drugs and bulk pharmaceutical products.
- Offer functional food products and healthcare services.
- Provide treatments for various health conditions, including cancer and neurological disorders.
- Engage in international sales and distribution of pharmaceutical products.
- Focus on innovation and quality in drug development and manufacturing.
Business Model
- Generate revenue through the sale of pharmaceutical products across various therapeutic areas.
- Leverage research and development to create innovative therapies that address unmet medical needs.
- Utilize a diversified product portfolio to mitigate risks associated with market fluctuations.
- Expand market presence through strategic partnerships and international distribution channels.
- Offer healthcare services and functional food products to diversify revenue streams.
Industry Context
The pharmaceutical industry is experiencing significant growth, driven by increasing healthcare demands and advancements in drug development. CSPC Pharmaceutical Group Limited operates within this dynamic landscape, where the global pharmaceutical market is projected to reach $1.5 trillion by 2023. The company faces competition from both domestic and international players, including peers such as ALBBY, BDUUY, BIOVF, ERFSF, and GIFLF. CSPC's strategic focus on innovation and its established presence in China provide a competitive edge as the industry evolves to meet changing healthcare needs.
Key Customers
- Hospitals and healthcare providers seeking pharmaceutical solutions.
- Patients requiring medications for chronic and acute health conditions.
- Distributors and wholesalers in the pharmaceutical supply chain.
- International markets looking for high-quality pharmaceutical products.
- Healthcare institutions requiring functional food and healthcare services.
Financials
Chart & Info
CSPC Pharmaceutical Group Limited (CHJTF) stock price: Price data unavailable
Latest News
No recent news available for CHJTF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CHJTF.
Price Targets
Wall Street price target analysis for CHJTF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CHJTF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lei Cai
CEO
Lei Cai has extensive experience in the pharmaceutical industry, having held various leadership positions since joining CSPC Pharmaceutical Group Limited. With a strong educational background in pharmaceutical sciences, he has been instrumental in driving the company's strategic vision and operational excellence.
Track Record: Under Lei Cai's leadership, CSPC has achieved significant growth in revenue and market share, while expanding its product portfolio and international presence. His focus on innovation and quality has positioned the company as a leader in the pharmaceutical sector.
CHJTF OTC Market Information
The OTC Other tier includes companies that trade on the over-the-counter market but do not meet the requirements for higher tiers like OTCQX or OTCQB. This tier typically has less stringent reporting requirements, which may affect transparency and investor confidence.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure compared to companies listed on major exchanges.
- Lower liquidity may result in higher volatility and trading difficulties.
- Potential for less regulatory oversight affecting investor confidence.
- Risks associated with foreign exchange fluctuations impacting earnings.
- Verify the company's financial statements and disclosures.
- Assess the competitive landscape and market position.
- Review recent news and developments impacting the company.
- Evaluate the management team's track record and experience.
- Consider the company's growth strategy and market opportunities.
- Established presence in the pharmaceutical industry since 1992.
- Strong product portfolio with a focus on innovation and quality.
- Positive financial metrics indicating operational efficiency.
- Recognition and partnerships with healthcare providers and institutions.
What Investors Ask About CSPC Pharmaceutical Group Limited (CHJTF)
What does CSPC Pharmaceutical Group Limited do?
CSPC Pharmaceutical Group Limited is engaged in the research, development, manufacture, and sale of a diverse range of pharmaceutical products. The company focuses on addressing various health conditions through innovative therapies and operates in multiple segments, including Finished Drugs, Bulk Products, and Functional Food.
What do analysts say about CHJTF stock?
Analysts generally view CHJTF stock favorably, noting its strong market position and growth potential. Key valuation metrics such as a P/E ratio of 22.48 and a profit margin of 14.9% indicate a solid financial foundation. Analysts also highlight the company's commitment to R&D as a driver for future growth.
What are the main risks for CHJTF?
CSPC Pharmaceutical Group Limited faces several risks, including regulatory challenges that could impact its ability to enter international markets. Additionally, the company is exposed to intense competition from both domestic and international pharmaceutical firms, which may affect market share and pricing strategies. Patent expirations on key products also pose a risk to revenue generation.
What are the key factors to evaluate for CHJTF?
CSPC Pharmaceutical Group Limited (CHJTF) currently holds an AI score of 50/100, indicating moderate score. Key strength: Diverse product portfolio catering to various health conditions.. Primary risk to monitor: Potential: Regulatory challenges in international markets may hinder growth.. This is not financial advice.
How frequently does CHJTF data refresh on this page?
CHJTF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CHJTF's recent stock price performance?
Recent price movement in CSPC Pharmaceutical Group Limited (CHJTF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse product portfolio catering to various health conditions.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CHJTF overvalued or undervalued right now?
Determining whether CSPC Pharmaceutical Group Limited (CHJTF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CHJTF?
Before investing in CSPC Pharmaceutical Group Limited (CHJTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information as of March 2026.